

## Performance in Delivering Research (PID) Q1 2017/18

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total No. Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
15/EM/0305	172320	CANC - 4278 - GTx-024 in Advanced, AR+ TNBC: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)	Number Agreed	2	Date Agreed	02/09/2016	0	12/09/2016	Withdrawn By Sponsor	Unable to achieve recruitment target as Sponsor withdrew the study in the UK due to lack of recruitment.
15/EE/0385	187687	NEPTUNE Lung: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non	Number Agreed	4	Date Agreed	24/09/2018	5	07/09/2016	Withdrawn By Host	Target Achieved
14/LO/0135	129217	BAYER 15396: A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subject	Number Agreed	6	Date Agreed	30/07/2021	5	22/08/2016	Recruitment Finished	Study closed as recruitment target achieved nationally.

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total No. Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
15/LO/0448	171812	RAINFALL: NCRN3464 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Number A	12	Date Agree	31/12/2018	8	18/08/2016	Recruitment Finished	Study closed earlier than planned as recruitment target achieved nationally.
15/EE/0013	170877	A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with o	Number A	4	Date Agree	27/05/2016	8	13/07/2016	Recruitment Finished	Target Achieved
15/NW/0690	177116	MK-3475-054: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group	Number A	3	Date Agree	01/03/2024	2	11/10/2016	Recruitment Finished	5 patients consented, 3 were ineligible following screening tests and 2 were recruited.
15/LO/0897	171318	WO29637 - MPDL3280A in renal cell: A phase III, open-label, randomized study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma	Number A	6	Date Agree	21/10/2016	13	12/10/2016	Recruitment Finished	Target achieved

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total No. Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
14/LO/1151	157354	A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy	Number A	15	Date Agreed	31/12/2016	14	28/11/2016	Recruitment Finished	Target Achieved
15/NW/0671	184963	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma	Number A	5	Date Agreed	31/03/2018	2	21/12/2016	Recruitment Finished	Rare cancer group with unwell patients. Study was difficult to recruit to in this population. 23 screened in total.
16/LO/085	200094	A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)	Number A	3	Date Agreed	06/03/2017	4	23/01/2017	Recruitment Finished	Target Achieved
15/NW/0713	171836	A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTX-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women	Number A	2	Date Agreed	31/10/2018	3	17/02/2017	Recruitment Finished	Target Achieved
15/EM/0546	194511	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients (KESTREL)	Number A	4	Date Agreed	10/02/2018	2	20/03/2017	Withdrawn By Sponsor	Rare cancer group, Sponsor closed study recruitment earlier than planned.

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total No. Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
14/EM/0089	137994	A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients.	Number A	2	Date Agreed	13/06/2017	2	29/03/2017	Recruitment Finished	Target Achieved
14/SC/1156	158604	A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis.	Number A	2	Date Agreed	31/05/2019	0	27/04/2017	Recruitment Finished	Rare cancer group with unwell patients. Study was difficult to recruit to in this population
16/NE/0028	188506	An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations	Number A	6	Date Agreed	30/11/2017	4	09/05/2017	Recruitment Finished	67% of target achieved